Proof of Concept Study of OC000459 in Eosinophilic Esophagitis

Summary

This will be a randomised, double blind, placebo controlled, parallel group evaluation of the effect of OC000459 given orally for eight weeks on active eosinophilic esophagitis.

Timeline

Start

2010-08

Primary completion

2011-06

Completion

2011-06

Drugs

Indications